EP1635849A1 - Medicament for internal application, in particular against cancerous diseases - Google Patents

Medicament for internal application, in particular against cancerous diseases

Info

Publication number
EP1635849A1
EP1635849A1 EP04733761A EP04733761A EP1635849A1 EP 1635849 A1 EP1635849 A1 EP 1635849A1 EP 04733761 A EP04733761 A EP 04733761A EP 04733761 A EP04733761 A EP 04733761A EP 1635849 A1 EP1635849 A1 EP 1635849A1
Authority
EP
European Patent Office
Prior art keywords
surfactants
polydimethylsiloxane
weight
proportion
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04733761A
Other languages
German (de)
French (fr)
Inventor
Gerd THÖNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bauer Wulf Dr
Original Assignee
Bauer Wulf Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bauer Wulf Dr filed Critical Bauer Wulf Dr
Publication of EP1635849A1 publication Critical patent/EP1635849A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a remedy for internal use, especially against cancer.
  • This object is achieved by a remedy which has polydimethylsiloxane and surfactants, the proportion of polydimethylsiloxane exceeding the proportion of surfactants.
  • the special feature of the invention is that the effect according to the invention is achieved only by adding surfactants.
  • Mixing the polydimethylsiloxane with surfactants means that the body is given the opportunity to emulsify the siloxane and make it usable. This is achieved by the surfactants breaking up the molecular structure of the polydimethylsiloxane.
  • the proportion of surfactants, based on the weight of the solution, can be significantly lower than the proportion of polydimethylsiloxane.
  • Anionic, amphoteric and nonionic surfactants can be used, the proportion by weight of the anionic surfactants exceeding the proportion by weight of the amphoteric and nonionic.
  • Polydimethylsiloxane is made from raw silicon.
  • Raw silicon is obtained from sand and coal, which is further processed into the desired silicones in a continuous process.
  • Natural gas or crude oil are used to produce methanol (synthesis gas), another starting material for silicone synthesis.
  • Chlorine is obtained by electrolysis of rock salt solutions and is added to the process in the form of HC1.
  • methanol is converted to chloromethane with HC1 (chloromethane synthesis).
  • a mixture of crude silanes (chlorosilane synthesis) is then obtained by reacting chloromethane with silicon. These are separated by distillation, dichlorodimethylsilane (CH3) 2SiC12 then being converted into polydimethylsiloxane by hydrolysis.
  • the remedy is nebulized using suitable nebulization techniques.
  • suitable nebulization techniques Various devices are available for this:
  • Compressed air operated Venturi nozzle nebulizer a) direct nebulization b) with aerosol reservoir c) with positive pressure inhalation 2.
  • Mechanical single-component jet nebulizer a) direct nebulization b) with aerosol reservoir c) with positive pressure inhalation 2.
  • aluminum silicate in particular natural zeolite with a grain size of 10 ⁇ m to 70 ⁇ m, in particular 40 ⁇ m and dolomite powder with a grain size of 2 ⁇ m to 30 ⁇ m, in particular 10 ⁇ m, can also be added. This results in powder that can be administered in capsules.
  • the basic skeleton of the crystal lattice of the zeolite consists primarily of SiÜ4 tetrahedra. It has cavities in which ions, e.g. B. are sodium, potassium and calcium, which can be easily exchanged with themselves and with their substrate environment.
  • This mineral-specific crystal structure (cage structure) of zeolite has the excellent property in living organisms, toxic substances, such as. B. ammonia and other nitrogen compounds, but also heavy metals, to bind (absorb) and excrete via the intestinal metabolism. The extracted toxic substances are exchanged for minerals that the body urgently needs. In this way, the homeostasis of the organism, in particular that of the mineral metabolism, is maintained or restored.
  • the zeolite also has a positive stimulating effect on the entire metabolism and in the growth and healing processes of the organism.
  • zeolite Because of its open molecular structure, zeolite also has the ability to absorb large quantities of liquids. This is advantageous since, despite mixing with the additional components mentioned above, a flowable powder can be formed.
  • the additional components may have the proportions in the end product:
  • Aluminum silicate 50 to 90, in particular 70% by weight,
  • the resulting mixture is a flowable powder and can be processed into a remedy in a variety of ways. It is thus possible to encapsulate the powdery mixture, for example in the form of the widely used gelatin capsules, which dissolve in the digestive tract. In addition, it is readily possible to press tablets from the powdered mixture, which can be taken with or without liquid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a medicament for internal application, in particular against cancerous diseases. The medicament comprises polydimethylsiloxane and surfactants, whereby the proportion of polydimethylsiloxane is greater than the proportion of surfactants.

Description

Bezeichnung: Heilmittel zur inneren Anwendung, insbesondere gegen KrebserkrankungenName: Remedy for internal use, especially against cancer
Die vorliegende Erfindung betrifft ein Heilmittel für eine innere Anwendung, insbesondere gegen Krebserkrankungen.The present invention relates to a remedy for internal use, especially against cancer.
Seit langem besteht ein Bedarf an Heilmitteln gegen Krebserkrankungen. Zwar sind Heilmittel bekannt und werden auch eingesetzt, jedoch sind diese oftmals mit erheblichen Nebenwirkungen verbunden. Auch sind die derzeit eingesetzten Heilmittel nicht zuletzt wegen ihrer aufwendigen Herstellung sehr teuer. Es besteht deshalb weiterhin der Wunsch nach verträglichen und kostengünstigen Heilmitteln für diesen Bereich.There has long been a need for cures for cancer. Although remedies are known and are also used, they are often associated with considerable side effects. The remedies currently used are also very expensive, not least because of their complex production. There is therefore still a desire for compatible and inexpensive remedies for this area.
Hier setzt nun die Erfindung ein. Sie hat es sich zur Aufgabe gemacht, ein Heilmittel zur inneren Anwendung, insbesondere gegen Krebskrankungen, anzugeben, mit dem ein möglichst wirkungsvolles Bekämpfen von Krebstumoren möglich ist. Die Nebenwirkungen sollen dabei möglichst gering und das Heilmittel möglichst kostengünstig sein.This is where the invention begins. It has set itself the task of specifying a cure for internal use, in particular against cancer, with which the most effective fight against cancerous tumors is possible. The side effects should be as low as possible and the remedy should be as inexpensive as possible.
Gelöst wird diese Aufgabe durch ein Heilmittel, das Polydimethylsiloxan und Tenside aufweist, wobei der Anteil an Polydimethylsiloxan den Anteil an Tensiden übersteigt.This object is achieved by a remedy which has polydimethylsiloxane and surfactants, the proportion of polydimethylsiloxane exceeding the proportion of surfactants.
Die Besonderheit der Erfindung besteht darin, dass nur durch die Zugabe von Tensiden die erfindungsgemäße Wirkung erzielt wird. Die Vermischung des Polydimethylsiloxane mit Tensiden bewirkt nämlich, dass dem Körper die Möglichkeit gegeben wird, das Siloxan zu emulgieren und nutzbar zu machen. Dies wird dadurch erreicht, dass die Tenside die Molekülstruktur des Polydimethylsiloxans aufbrechen. Der Anteil an Tensiden kann bezogen auf das Gewicht der Lösung deutlich geringer sein als der Anteil an Polydimethylsiloxan. Es können anionische, amphotere und nichtionische Tenside verwendet werden, wobei der Gewichtsanteil der anionischen Tenside den Gewichtsanteil der amphoteren und nichtionischen übersteigt.The special feature of the invention is that the effect according to the invention is achieved only by adding surfactants. Mixing the polydimethylsiloxane with surfactants means that the body is given the opportunity to emulsify the siloxane and make it usable. This is achieved by the surfactants breaking up the molecular structure of the polydimethylsiloxane. The proportion of surfactants, based on the weight of the solution, can be significantly lower than the proportion of polydimethylsiloxane. Anionic, amphoteric and nonionic surfactants can be used, the proportion by weight of the anionic surfactants exceeding the proportion by weight of the amphoteric and nonionic.
In diesem Zusammenhang ist zu erwähnen, dass die meisten Vorkommen von Silizium, selbst das Bergkristall, welches aus purem Silizium besteht, keine bioaktive Wirkung besitzen. Diese Eigenschaft wird, wie bereits ausgeführt, erst durch die Zugabe von Tensiden erreicht.In this context it should be mentioned that most deposits of silicon, even the rock crystal, which consists of pure silicon, have no bioactive effect. As already stated, this property is only achieved by adding surfactants.
Polydimethylsiloxan wird Rohsilizium hergestellt. Aus Sand und Kohle wird Rohsilizium gewonnen, das in einem kontinuierlichen Prozess zu den gewünschten Siliconen weiterverarbeitet wird. Erdgas oder Erdöl dienen dazu, Methanol herzustellen (Synthesegas), ein weiterer Ausgangs stoff zur Siliconsynthese. Durch Elektrolyse von Steinsalzlösungen wird Chlor gewonnen, das in Form von HC1 dem Prozess zugeführt wird.Polydimethylsiloxane is made from raw silicon. Raw silicon is obtained from sand and coal, which is further processed into the desired silicones in a continuous process. Natural gas or crude oil are used to produce methanol (synthesis gas), another starting material for silicone synthesis. Chlorine is obtained by electrolysis of rock salt solutions and is added to the process in the form of HC1.
Im ersten Schritt wird Methanol mit HC1 zu Chlormethan umgesetzt (Chlormethansynthese) . Anschließend gewinnt man durch Reaktion von Chlormethan mit Silizium ein Gemisch von Rohsilanen (Chlorsilansynthese) . Diese werden durch Destillation getrennt, wobei Dichlordimethylsilan (CH3)2SiC12 dann durch Hydrolyse in Polydimethylsiloxan überführt wird.In the first step, methanol is converted to chloromethane with HC1 (chloromethane synthesis). A mixture of crude silanes (chlorosilane synthesis) is then obtained by reacting chloromethane with silicon. These are separated by distillation, dichlorodimethylsilane (CH3) 2SiC12 then being converted into polydimethylsiloxane by hydrolysis.
Es ist grundsätzlich möglich, das erfindungsgemäße Heilmittel zu inhalieren. Zur Inhalation wird das Heilmittel mittels geeigneter Vernebelungstechniken apparativ vernebelt. Hierzu werden verschiedene Apparaturen angeboten:In principle, it is possible to inhale the medicinal product according to the invention. For inhalation, the remedy is nebulized using suitable nebulization techniques. Various devices are available for this:
1. Pressluft betriebener Venturi-Düsenvernebler: a) direkte Vernebelung b) mit Aerosolreservoir c) mit Überdruckinhalat 2. Mechanischer Einstoff-Düsenvernebler1. Compressed air operated Venturi nozzle nebulizer: a) direct nebulization b) with aerosol reservoir c) with positive pressure inhalation 2. Mechanical single-component jet nebulizer
3. Ultraschallvernebelung3. Ultrasonic nebulization
4. Ultraschalldruck über perforiertes Sieb4. Ultrasonic printing over perforated screen
5. Ultraschallgetriebene perforierte Membran5. Ultrasound-driven perforated membrane
6. Elektromechanischer Druck durch perforierte Membran6. Electromechanical pressure through perforated membrane
Die Inhalation mit einer Atemmaske sowie mit einem mit Mundstück oder einem Nasenstück haben sich als gut geeignet erwiesen.Inhalation with a breathing mask as well as with a mouthpiece or a nose piece has proven to be well suited.
Neben den genannten Bestandteilen kann zusätzlich Aluminiumsilikat, insbesondere Naturzeolith mit einer Korngröße von 10 μm bis 70 μm, insbesondere 40 μm und Dolomitpulver mit einer Korngröße von 2 μm bis 30 μm, insbesondere 10 μm zugesetzt werden. Somit ergibt sich Pulver, das in Kapseln verabreicht werden kann.In addition to the components mentioned, aluminum silicate, in particular natural zeolite with a grain size of 10 μm to 70 μm, in particular 40 μm and dolomite powder with a grain size of 2 μm to 30 μm, in particular 10 μm, can also be added. This results in powder that can be administered in capsules.
Das Grundskelett des Kristallgitters des Zeoliths besteht in erster Linie aus SiÜ4 Tetraedern. Es weist Hohlräume auf, in denen sich Ionen, z. B. Natrium, Kalium und Calcium befinden, die sich mit sich und mit ihrer Substratumgebung leicht austauschen lassen. Diese mineralstoffspezifische Kristallstruktur (Käfigstruktur) von Zeolith hat in lebenden Organismen die vorzügliche Eigenschaft, toxische Stoffe, wie z. B. Ammoniak und andere Stickstoffverbindungen, aber auch Schwermetalle, an sich zu binden (absorbieren) und über den Darmstoffwechsel auszuscheiden. Die entzogenen toxischen Stoffe werden gegen Mineralien ausgetauscht, die der Körper dringend benötigt. Auf diese Weise wird die Homöostase des Organismus, insbesondere die des Mineralstoffwechsels, aufrechterhalten bzw. wieder hergestellt.The basic skeleton of the crystal lattice of the zeolite consists primarily of SiÜ4 tetrahedra. It has cavities in which ions, e.g. B. are sodium, potassium and calcium, which can be easily exchanged with themselves and with their substrate environment. This mineral-specific crystal structure (cage structure) of zeolite has the excellent property in living organisms, toxic substances, such as. B. ammonia and other nitrogen compounds, but also heavy metals, to bind (absorb) and excrete via the intestinal metabolism. The extracted toxic substances are exchanged for minerals that the body urgently needs. In this way, the homeostasis of the organism, in particular that of the mineral metabolism, is maintained or restored.
Somit werden empfindliche Organsysteme, z. B. Gehirn, Nervensystem, Hormonsystem, Immunsystem, Leber, Nieren u. a. nicht nur von toxischen Schäden geschützt, sondern auch ihre Widerstandsfähigkeit gegenüber schädlichen pathogenen Einflüssen erhöht Das Zeolith greift außerdem, wie das Silizium, positiv stimulierend in den gesamten Stoffwechsel und in die Wachstums- und Heilungsprozesse des Organismus ein.Thus sensitive organ systems, e.g. B. brain, nervous system, hormone system, immune system, liver, kidneys, among other things, not only protected from toxic damage, but also increases their resistance to harmful pathogenic influences Like the silicon, the zeolite also has a positive stimulating effect on the entire metabolism and in the growth and healing processes of the organism.
Zeolith hat zudem wegen seiner offenen Molekülstruktur die Fähigkeit, größere Mengen Flüssigkeiten aufzunehmen. Dies ist vorteilhaft, da dadurch trotz Vermischung mit den oben genannten zusätzlichen Bestandteilen ein fließfähiges Pulver gebildet werden kann.Because of its open molecular structure, zeolite also has the ability to absorb large quantities of liquids. This is advantageous since, despite mixing with the additional components mentioned above, a flowable powder can be formed.
Beispielsweise können die zusätzlichen Bestandteile die Anteile im Endprodukt aufweisen:For example, the additional components may have the proportions in the end product:
- Aluminiumsilikat: 50 bis 90, insbesondere 70 Gew.%,Aluminum silicate: 50 to 90, in particular 70% by weight,
- Dolomitpulver: 5 bis 45, insbesondere 25 Gew.%.- Dolomite powder: 5 to 45, in particular 25% by weight.
Die so entstehende Mischung ist ein fließfähiges Pulver und kann auf vielfältige Weise zu einem Heilmittel verarbeitet werden. So ist es möglich, die pul- verförmige Mischung zu verkapseln, beispielsweise in Form der weit verbreiteten Gelatinekapseln, die sich im Verdauungstrakt auflösen. Darüber hinaus ist es ohne weiteres möglich, aus der pulverförmigen Mischung Tabletten zu pressen, die mit oder ohne Flüssigkeit eingenommen werden können.The resulting mixture is a flowable powder and can be processed into a remedy in a variety of ways. It is thus possible to encapsulate the powdery mixture, for example in the form of the widely used gelatin capsules, which dissolve in the digestive tract. In addition, it is readily possible to press tablets from the powdered mixture, which can be taken with or without liquid.
Es hat sich gezeigt, dass die Lösungen gegen Krebszellen wirksam sind, jedoch keinen Einfluss auf gesunde Zellen haben.The solutions against cancer cells have been shown to be effective, but have no effect on healthy cells.
Es hat sich in klinischen Versuchen gezeigt, dass das erfindungsgemäße Heilmittel folgende Wirkungen aufweist:Clinical trials have shown that the medicinal product according to the invention has the following effects:
- bessere Verträglichkeit von Chemo- und Strahlentherapien,- better tolerance of chemotherapy and radiation therapies,
- Stornieren des Tumorwachstums,- Canceling tumor growth,
- Verhärten (Mineralisieren des Tumors),Hardening (mineralization of the tumor),
- Teilweise Einkapseln und Reduzierung des Tumors, - Verbesserung des Allgemeinzustandes,- partial encapsulation and reduction of the tumor, - improvement of general condition,
- Beseitigung von entzündlichen Prozessen als Nebenwirkung der Strahlen und Chemotherapie, z.B. der Mundschleimhaut.- Eliminate inflammatory processes as a side effect of radiation and chemotherapy, e.g. the oral mucosa.
Außerdem hat sich in ersten Tests erwiesen, dass das erfindungsgemäße Heilmittel virenhemmend wirkt. Es haben sich erste Erfolge bezüglich der Behandlung von AIDS (HIV) und SARS gezeigt. Diesbezüglich behält sich der Anmelder eine Teilanmeldung vor. In addition, it has been shown in initial tests that the medicinal product according to the invention has an antiviral effect. The first successes with the treatment of AIDS (HIV) and SARS have been shown. In this regard, the applicant reserves a divisional application.

Claims

Bezeichnung: Heilmittel zur inneren Anwendung, insbesondere gegen KrebserkrankungenPatentansprüche Description: Medicinal product for internal use, especially against cancer
1. Heilmittel zur inneren Anwendung, insbesondere gegen Krebserkrankungen, gekennzeichnet durch die Bestandteile Polydimethylsiloxan und Tenside, wobei der Anteil an Polydimethylsiloxan den Anteil an Tensiden übersteigt.1. Remedies for internal use, in particular against cancer, characterized by the components polydimethylsiloxane and surfactants, the proportion of polydimethylsiloxane exceeding the proportion of surfactants.
2. Heilmittel nach Anspruch 1, dadurch gekennzeichnet, dass in der Mischung der beiden Bestandteile der Anteil an Polydimethylsiloxan etwa 90-99,9, insbesondere 99 Gew.% und der Anteil an Tensiden von 0, 1- 10, insbesondere 1 Gew.% beträgt.2. Medicament according to claim 1, characterized in that in the mixture of the two constituents the proportion of polydimethylsiloxane is approximately 90-99.9, in particular 99% by weight and the proportion of surfactants is 0.1-1, in particular 1% by weight. is.
3. Heilmittel nach Anspruch 1 oder Anspruch 2, dadurch gekennzeichnet, dass zusätzlich Aluminiumsilikat, insbesondere Naturzeolith mit einer Korngröße von 10 μm bis 70 μm, insbesondere 40 μm und Dolomitpulver mit einer Korngröße von 2 μm bis 30 μm, insbesondere 10 μm zugesetzt ist.3. Medicinal product according to claim 1 or claim 2, characterized in that aluminum silicate, in particular natural zeolite with a grain size of 10 μm to 70 μm, in particular 40 μm and dolomite powder with a grain size of 2 μm to 30 μm, in particular 10 μm, is additionally added.
4. Heilmittel nach Anspruch 3, dadurch gekennzeichnet, dass die zusätzlichen Bestandteile folgende Anteile im Endprodukt aufweisen:4. Medicinal product according to claim 3, characterized in that the additional components have the following proportions in the end product:
- Aluminiumsilikat: 50 bis 90, insbesondere 70 Gew.%,Aluminum silicate: 50 to 90, in particular 70% by weight,
- Dolomitpulver: 5 bis 45, insbesondere 25 Gew.%.- Dolomite powder: 5 to 45, in particular 25% by weight.
5. Heilmittel nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass anionische, amphotere und nichtionische Tenside enthalten sind, wobei der Gewichtsanteil der anionischen Tenside den Gewichtsanteil der amphoteren und nichtionischen Tenside überwiegt. 5. Medicinal product according to one of claims 1 to 4, characterized in that it contains anionic, amphoteric and nonionic surfactants, the weight fraction of the anionic surfactants outweighing the weight fraction of the amphoteric and nonionic surfactants.
6. Verwendung von Polydimethylsiloxan und Tensiden zur Herstellung eines Heilmittels zur inneren Anwendung, insbesondere gegen Krebserkrankungen.6. Use of polydimethylsiloxane and surfactants for the manufacture of a medicinal product for internal use, in particular against cancer.
7. Verwendung von Polydimethylsiloxan und Tensiden zur Herstellung eines Heilmittels nach Anspruch 7, dadurch gekennzeichnet, dass in der Mischung der beiden Bestandteile der Anteil an Polydimethylsiloxan etwa 90 - 99,9, insbesondere 99 Gew.% und der Anteil an Tensiden von 0, 1°- 10, insbesondere 1 Gew.% beträgt.7. Use of polydimethylsiloxane and surfactants for the production of a medicinal product according to claim 7, characterized in that in the mixture of the two constituents the proportion of polydimethylsiloxane is approximately 90-99.9, in particular 99% by weight and the proportion of surfactants is 0.1 ° - 10, in particular 1% by weight.
8. Verwendung von Polydimethylsiloxan und Tensiden zur Herstellung eines Heilmittels nach Anspruch 6 oder Anspruch 7, dadurch gekennzeichnet, dass zusätzlich Aluminiumsilikat, insbesondere Naturzeolith mit einer Korngröße von 10 bis 70, insbesondere 40 μm und Dolomitpulver mit einer Korngröße von 2 bis 30, insbesondere 10 μm zugesetzt ist.8. Use of polydimethylsiloxane and surfactants for the preparation of a medicament according to claim 6 or claim 7, characterized in that in addition aluminum silicate, in particular natural zeolite with a grain size of 10 to 70, in particular 40 μm and dolomite powder with a grain size of 2 to 30, in particular 10 μm is added.
9. Verwendung von Polydimethylsiloxan und Tensiden zur Herstellung eines Heilmittels nach einem der Ansprüche 6 bis 8, dadurch gekennzeichnet, dass die zusätzlichen Bestandteile folgende Anteile im Endprodukt aufweisen:9. Use of polydimethylsiloxane and surfactants for the production of a medicinal product according to one of claims 6 to 8, characterized in that the additional components have the following proportions in the end product:
- Aluminiumsilikat: 50 bis 90, insbesondere 70 Gew.%,Aluminum silicate: 50 to 90, in particular 70% by weight,
- Dolomitpulver: 5 bis 45, insbesondere 25 Gew.%.- Dolomite powder: 5 to 45, in particular 25% by weight.
10. Verwendung von Polydimethylsiloxan und Tensiden zur Herstellung eines Heilmittels nach einem der Ansprüche 6 bis 9, dadurch gekennzeichnet, dass anionische, amphotere und nichtionische Tenside enthalten sind, wobei der Gewichtsanteil der anionischen Tenside den Gewichtsanteil der amphoteren und nichtionischen Tenside überwiegt. 10. Use of polydimethylsiloxane and surfactants for the production of a medicament according to one of claims 6 to 9, characterized in that anionic, amphoteric and nonionic surfactants are contained, the weight fraction of the anionic surfactants outweighing the weight fraction of the amphoteric and nonionic surfactants.
EP04733761A 2003-05-22 2004-05-19 Medicament for internal application, in particular against cancerous diseases Withdrawn EP1635849A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10323758A DE10323758A1 (en) 2003-05-22 2003-05-22 Remedies for internal use, especially against cancer
PCT/DE2004/001048 WO2004105776A1 (en) 2003-05-22 2004-05-19 Medicament for internal application, in particular against cancerous diseases

Publications (1)

Publication Number Publication Date
EP1635849A1 true EP1635849A1 (en) 2006-03-22

Family

ID=33441299

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04733761A Withdrawn EP1635849A1 (en) 2003-05-22 2004-05-19 Medicament for internal application, in particular against cancerous diseases

Country Status (9)

Country Link
US (1) US20070172435A1 (en)
EP (1) EP1635849A1 (en)
JP (1) JP2006528211A (en)
CN (1) CN1795001A (en)
AU (1) AU2004243524A1 (en)
CA (1) CA2526175A1 (en)
DE (1) DE10323758A1 (en)
RU (1) RU2005140097A (en)
WO (1) WO2004105776A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323759A1 (en) * 2003-05-22 2004-12-16 Bauer, Wulf, Dr. Remedies for internal use, especially against cancer
DE102007043758A1 (en) 2007-09-13 2008-10-23 Basf Se Target product continuous separating operation in form of fine crystals from liquid phase, includes heat exchanger having secondary space and primary space
DE102007043759A1 (en) 2007-09-13 2008-09-11 Basf Se Procedure for continuous separation of target product in the form of fine particle of crystallisate, comprises indirectly operating a heat exchanger having primary and secondary areas, which are spatially separated with one another
BE1018537A3 (en) 2007-09-13 2011-03-01 Basf Se METHOD FOR OPERATING A CONTINUOUS SEPARATION OF TARGET PRODUCT X IN THE FORM OF A FINALLY DIVIDED CRYSTALLISATE
DE102007043748A1 (en) 2007-09-13 2008-09-11 Basf Se Method for separating target product i.e. acrylic acid, methacrylic acid, p-xylene or N-vinylpyrrolidone in form of fine crystallized product, involves utilizing heat exchanger, where heat flow is gathered from heat exchanger
DE102009045767A1 (en) 2009-10-16 2010-08-12 Basf Se Method for commissioning process for purified separation of acrylic acid crystals from suspension of its crystals in mother liquor with device having hydraulic washing column that has process chamber limited by a cylindrical lateral wall
US8461383B2 (en) 2009-10-16 2013-06-11 Basf Se Process for starting up a separating process for purifying removal of acrylic acid crystals from a suspension S of crystals thereof in mother liquor
DE102010030279A1 (en) 2010-06-18 2010-10-28 Basf Se Method for cleaning separation of acrylic acid crystals from a suspension of its crystals in mother liquor using a device having a hydraulic washing column, comprises carrying out crystallization of acrylic acid during cooling
AU2015354399B2 (en) * 2014-11-24 2020-05-14 Bio-Latem Technologies Pty Limited Methods for the treatment and prevention of asbestos-related diseases
CN104606261B (en) * 2015-03-05 2018-02-09 潘友长 A kind of zeolite pharmaceutical composition and its production and use
CN105837734A (en) * 2016-05-09 2016-08-10 上海惠昌化工厂 Organosilicone modified acrylic polyester potash, preparation method and application to cancer prevention and treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310572A (en) * 1987-02-03 1994-05-10 Dow Corning Corporation Process for forming a coated active agent-containing article
US5418220A (en) * 1994-03-08 1995-05-23 Schmidt; Alfred Method for treating constipation using dimethicone
US5587149A (en) * 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
CA2285012C (en) * 1996-03-25 2006-06-20 Bauer, Wulf Remedy for external application, and use of an oil-in-water emulsion for said remedy
US6347408B1 (en) * 1998-11-05 2002-02-19 Allegiance Corporation Powder-free gloves having a coating containing cross-linked polyurethane and silicone and method of making the same
ATE365002T1 (en) * 1999-04-26 2007-07-15 Tihomir Lelas USE OF MICRONIZED ZEOLITES AS FILTER MATERIALS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004105776A1 *

Also Published As

Publication number Publication date
CA2526175A1 (en) 2004-12-09
WO2004105776A1 (en) 2004-12-09
JP2006528211A (en) 2006-12-14
DE10323758A1 (en) 2004-12-16
RU2005140097A (en) 2006-08-10
US20070172435A1 (en) 2007-07-26
AU2004243524A1 (en) 2004-12-09
CN1795001A (en) 2006-06-28

Similar Documents

Publication Publication Date Title
JP2021191766A (en) Compositions and methods for managing or improving bone disorders, cartilage disorders, or both of them
EP1635849A1 (en) Medicament for internal application, in particular against cancerous diseases
DE19749724A1 (en) Use of a combination of opioid and alpha-adrenergic agonist in pain relievers
DE10323759A1 (en) Remedies for internal use, especially against cancer
DE69100954T2 (en) Oral storage forms of oral glucosamine sulfate and methods for their preparation.
DE2504331A1 (en) HEPTAMINOL 5'-ADENOSINE MONOPHOSPHATE AND ITS THERAPEUTIC USE
DE1767017A1 (en) Iron preparation
DE2062715C3 (en) Process for the production of orally administrable pharmaceutical preparations with protracted active ingredient release and pharmaceutical preparation
JP2006528210A5 (en)
EP2897906B1 (en) Process for bio synthesis of nano arsenic trioxide and its use in treatment of diseases including cancers
DE2304705C2 (en) Dietary mineral supplement preparation
EP1524273A1 (en) Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(IV) salts and derivatives and their use for the preparation of pharmaceutical active agents
EP0256353A2 (en) Pharmaceutical therapy against the bad absorption of food or oral drugs
EP3373911B1 (en) Combination of calcium sulfate and gum arabic
DE1043587B (en) Process for making an appetite suppressant
EP2130545A2 (en) Solution and tincture
CN106806411A (en) External used medicine of respiratory disease symptom and preparation method thereof is alleviated in treatment
Odimegwu et al. Pharmaco-chemical analysis and in vivo toxicity assays of edible clays mined in nigeria and consumed globally
EP2509613A1 (en) Compound for treating gastrointestinal problems
DE69901843T2 (en) ONE OR MORE COMPONENTS OF MOTHER-OF-PEARL, INCLUDING BIO-ARAGONITE-CONTAINING HOMEOPATHIC MEDICINAL PRODUCT
RU2407537C1 (en) Method for treatment and prevention of gastrointestinal disturbances and pulmonary diseases in young animals and birds
US244965A (en) Medical compound
DE69730596T2 (en) COMBINED THE ALLOPATHIC AND ITS APPROPRIATE HOMEOPHATIC SUBSTANCES
DE629896C (en) Manufacture of reaction products from arsenic and arsenic acid
CN108310052A (en) It is a kind of to treat psoriasic Chinese herbal ointment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091201